Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 14,938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Completed Not applicable Interventional Results available

SpHincterotomy for Acute Recurrent Pancreatitis

NCT03609944
View directory record Official record
Conditions
Pancreatitis, Pancreas Divisum, Pancreatitis, Acute, Pancreatitis Idiopathic, Pancreas Inflamed
Interventions
ERCP with miES, EUS
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

NCT00909402
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
BMS-833923, Cisplatin, Capecitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 23, 2026, 6:56 AM EDT
Terminated Not applicable Interventional Results available

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions
Dietary and Lifestyle modification educational sessions
Behavioral
Lead sponsor
Hossam Kandil
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

NCT06615375
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella4V2, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

NCT04841057
View directory record Official record
Conditions
Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
Interventions
50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Flaxseed Modulates Inflammation and Oxidative Stress in CF

NCT02014181
View directory record Official record
Conditions
Cystic Fibrosis, Oxidative Stress, Inflammation
Interventions
finely ground flaxseed powder
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 23, 2026, 6:56 AM EDT
Withdrawn Phase 2 Interventional

Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT00882765
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
genistein
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 23, 2026, 6:56 AM EDT
Withdrawn Not applicable Interventional

Feasibility Study of LUM Imaging System for Pancreatic Cancer

NCT04276909
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 23, 2026, 6:56 AM EDT
Recruiting No phase listed Observational

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

NCT07717437
View directory record Official record
Conditions
Liver Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT01730937
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
Sorafenib, stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
41
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Recruiting Not applicable Interventional

Mindfulness-Based fMRI Neurofeedback for Depression

NCT05617495
View directory record Official record
Conditions
Depression in Adolescence, Rumination
Interventions
Mindfulness + fMRI Neurofeedback
Other
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 3 Interventional

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Patient Automated Text Hovering for IBD

NCT04388865
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Control, Text-based Clinical Hovering
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD

NCT00585299
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
Low-fat diet, Traditional diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 23, 2026, 6:56 AM EDT
Withdrawn Not applicable Interventional

Pancreatic Stent to Prevent Leak After Distal Pancreatectomy

NCT00671463
View directory record Official record
Conditions
Pancreatic Surgery, Pancreatic Duct Stenting, Pancreatic Cancer, Distal Pancreatectomy, Pancreatic Diseases, Pancreatic Cyst, Pancreatic Ducts
Interventions
Pancreatic duct stenting
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 23, 2026, 6:56 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study in Infant With SBS

NCT02865122
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NTRA-9620, Placebo
Drug
Lead sponsor
Elgan Pharma Ltd.
Industry
Eligibility
2 Weeks to 52 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Palo Alto, California • Hartford, Connecticut • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

NCT02837029
View directory record Official record
Conditions
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
Other · Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 23, 2026, 6:56 AM EDT
Not listed No phase listed Observational

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 23, 2026, 6:56 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

NCT01335945
View directory record Official record
Conditions
Pain, Pancreatic Cancer
Interventions
Cryoablation
Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Detroit, Michigan • Stony Brook, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 23, 2026, 6:56 AM EDT
Completed No phase listed Observational

Visualization of the Papilla Through Use of the NuView Device in Patients With FAP

NCT05657145
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Recruiting Phase 2 Interventional

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 6:56 AM EDT
Withdrawn Phase 1Phase 2 Interventional

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

NCT01600807
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic
Interventions
Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 23, 2026, 6:56 AM EDT
Completed Not applicable Interventional Results available

A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP

NCT04740164
View directory record Official record
Conditions
Bile Duct Carcinoma, Gallbladder Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
Endoscopic Retrograde Cholangiopancreatography
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 23, 2026, 6:56 AM EDT